Paris II criteria
"Most of the biochemical response criteria have been validated as predicting long-term disease progression at 12 months from UDCA initiation. However, it has also been demonstrated that evaluation at 6 months may be equally discriminatory. Patients deemed to be at intermediate-to-high risk of disease progression at the start of treatment should be evaluated at 6 months"